Healius Limited (ASX:HLS)
Australia
· Delayed Price · Currency is AUD | Market Cap | 497.40M |
| Revenue (ttm) | 1.37B |
| Net Income (ttm) | -168.80M |
| Shares Out | 726.13M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | 54.37 |
| Dividend | 0.41 (59.86%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 1,517,422 |
| Average Volume | 3,952,844 |
| Open | 0.700 |
| Previous Close | 0.690 |
| Day's Range | 0.680 - 0.700 |
| 52-Week Range | 0.660 - 1.635 |
| Beta | 0.35 |
| RSI | 26.15 |
| Earnings Date | Feb 18, 2026 |
About Healius
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ... [Read more]
Financial Performance
In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.
Financial StatementsNews
Healius Ltd (ASX:HLS) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Healius Ltd (ASX:HLS) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
Healius Limited (PHCRF) Q2 2026 Earnings Call Transcript
Healius Limited (PHCRF) Q2 2026 Earnings Call Transcript
Healius Limited (PHCRF) Shareholder/Analyst Call Transcript
Healius Limited (OTCPK:PHCRF) Shareholder/Analyst Call October 29, 2025 8:01 PM EDT Company Participants Kathryn McKenzie Paul Anderson - MD, CEO & Director Gillian Nairn Conference Call Participants ...